Drug-Induced Liver Injury in Pregnancy: The U.S. Drug-Induced Liver Injury Network Experience.
Journal
Obstetrics and gynecology
ISSN: 1873-233X
Titre abrégé: Obstet Gynecol
Pays: United States
ID NLM: 0401101
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
received:
28
01
2024
accepted:
14
03
2024
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
16
4
2024
Statut:
aheadofprint
Résumé
There are limited data on the causative agents and characteristics of drug-induced liver injury in pregnant individuals. Data from patients with drug-induced liver injury enrolled in the ongoing multicenter Drug-Induced Liver Injury Network between 2004 and 2022 and occurring during pregnancy or 6 months postpartum were reviewed and compared with cases of drug-induced liver injury in nonpregnant women of childbearing age. Among 325 individuals of childbearing age in the Drug-Induced Liver Injury Network, 16 cases of drug-induced liver injury (5%) occurred during pregnancy or postpartum. Compared with drug-induced liver injury in nonpregnant women, pregnancy-related drug-induced liver injury was more severe (P<.05). One elective termination and three miscarriages were documented; there were no maternal deaths. We recommend that isoniazid for latent tuberculosis be deferred to the postpartum period whenever feasible and that β-blockers or calcium channel blockers rather than methyldopa be used for hypertension management during pregnancy.
Identifiants
pubmed: 38626448
doi: 10.1097/AOG.0000000000005585
pii: 00006250-990000000-01056
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Financial Disclosure Paola Nicoletti has ongoing paid consulting activities with Astella and Chiesi Farmaceutici. Herbert Bonkovsky receives support for clinical research studies from Alnylam Pharma, Cymabay Pharma, Disc Medicine, and Mitsubishi-Tanabe, North America; funds are awarded to the Wake Forest University School of Medicine. In the past 3 years, Dr. Bonkovsky has served as a consultant to Alnylam Pharma, Bridge Bio, Disc Medicine, and Recordati Rare Chemicals. He serves on an hepatic adjudication committee for Eiger Pharma. Simona Rossi reports receiving payment from Gilead. Tatyana Kushner has participated in advisory boards for Gilead, AbbVie, Bausch, GSK, and Eiger and has research support from Gilead Sciences. The other authors did not report any potential conflicts of interest.
Références
Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ. LiverTox: a website on drug-induced liver injury. Hepatology 2013;57:873–4. doi: 10.1002/hep.26175
doi: 10.1002/hep.26175
Ahmad J, Odin JA, Hayashi PH, Chalasani N, Fontana RJ, Barnhart H, et al. Identification and characterization of fenofibrate-induced liver injury. Dig Dis Sci 2017;62:3596–604. doi: 10.1007/s10620-017-4812-7
doi: 10.1007/s10620-017-4812-7
Hayashi PH, Barnhart HX, Fontana RJ, Chalasani N, Davern TJ, Talwalkar JA, et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int 2015;35:1623–32. doi: 10.1111/liv.12540
doi: 10.1111/liv.12540
Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010;51:2117–26. doi: 10.1002/hep.23577
doi: 10.1002/hep.23577
Ahmad J, Barnhart HX, Bonacini M, Ghabril M, Hayashi PH, Odin JA, et al. Value of liver biopsy in the diagnosis of drug-induced liver injury. J Hepatol 2022;76:1070–8. doi: 10.1016/j.jhep.2021.12.043
doi: 10.1016/j.jhep.2021.12.043
Osterman MJK, Hamilton BE, Martin JA, Driscoll AK, Valenzuela CP. Births: final data for 2021. Natl Vital Stat Rep 2023;72:1–53.
Hutchinson TA, Lane DA. Assessing methods for causality assessment of suspected adverse drug reactions. J Clin Epidemiol 1989;42:5–16. doi: 10.1016/0895-4356(89)90020-6
doi: 10.1016/0895-4356(89)90020-6
Ludvigsson JF, Marschall HU, Hagstrom H, Höijer J, Stephansson O. Pregnancy outcome in women undergoing liver biopsy during pregnancy: a nationwide population-based cohort study. Hepatology 2018;68:625–33. doi: 10.1002/hep.29345
doi: 10.1002/hep.29345
Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Treatment for mild chronic hypertension during pregnancy. N Engl J Med 2022;386:1781–92. doi: 10.1056/NEJMoa2201295
doi: 10.1056/NEJMoa2201295
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of liver diseases in pregnancy. J Hepatol 2023;79:768–828. doi: 10.1016/j.jhep.2023.03.006
doi: 10.1016/j.jhep.2023.03.006
Ajayi AAL, Ajayi OE. Pathophysiologically based antihypertensive pharmacotherapeutics rationality, efficacy and safety in Sub Saharan African Nations—a review. Int J Cardiol Cardiovasc Risk Prev 2021;11:200111. doi: 10.1016/j.ijcrp.2021.200111
doi: 10.1016/j.ijcrp.2021.200111
Adams Waldorf KM, Nelson JL. Autoimmune disease during pregnancy and the microchimerism legacy of pregnancy. Immunol Invest 2008;37:631–44. doi: 10.1080/08820130802205886
doi: 10.1080/08820130802205886